피부 T세포 림프종 시장 : 역학 기반 현재의 시장 가치(2021년)와 예측(-2030년), 경쟁 신약의 가격 전략, 거래 가치 평가, r-NPV, 파이프라인약 분석(2022년 상반기)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 피부 T세포 림프종 시장에 대해 조사했으며, 시장의 개요와 2030년까지의 예측, 파이프라인 동향, 경쟁 전략 등을 정리하여 전해드립니다.

목차

제1장 서론

제2장 개요

제3장 피부 T세포 림프종의 개요와 역학 연구

제4장 피부 T세포 림프종의 현재 시장 가치와 예측 : 2021-2030년

제5장 파이프라인 인사이트와 벤치마킹 개요

제6장 피부 T세포 림프종 경쟁 분야에서의 거래 활동

제7장 피부 T세포 림프종 파이프라인약의 비교 특허 분석

제8장 리스크 조정 순현재가치(R-NPV) 분석

제9장 경쟁 기회 평가

제10장 시장 역학

제11장 경쟁사 신약의 가격 전략

LIST OF TABLES

(COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

• TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS
• TABLE 02: WORLDWIDE EPIDEMIOLOGY INSIGHTS OF CUTANEOUS T-CELL LYMPHOMA
• TABLE 03: GLOBAL CUTANEOUS T-CELL LYMPHOMA EPIDEMIOLOGY (2020), FORECAST (2021-2030)
• TABLE 04: US CUTANEOUS T-CELL LYMPHOMA EPIDEMIOLOGY (2020), FORECAST (2021-2030)
• TABLE 05: UK CUTANEOUS T-CELL LYMPHOMA EPIDEMIOLOGY (2020), FORECAST (2021-2030)
• TABLE 06: LIST OF NEW ENTRANTS CONSIDERED FOR MARKET ESTIMATIONS
• TABLE 07: CUTANEOUS T-CELL LYMPHOMA GLOBAL CURRENT MARKET (2020), FORECAST (2021-2030)
• TABLE 08: CUTANEOUS T-CELL LYMPHOMA US CURRENT MARKET (2020), FORECAST (2021-2030)
• TABLE 09: COMPARISON OF CUTANEOUS T-CELL LYMPHOMA MARKET VALUES GLOBAL VERSUS US (2020-2030)(M$)
• TABLE 10: PIPELINE ASSETS IN CUTANEOUS T-CELL LYMPHOMA DRUG PIPELINE
• TABLE 11: SPECIAL REGULATORY ALLOWANCES GRANTED FOR CUTANEOUS T-CELL LYMPHOMA PIPELINE DRUGS
• TABLE 12: CUTANEOUS T-CELL LYMPHOMA PIPELINE ANALYTICS BY ROUTE OF ADMINISTRATION
• TABLE 13: CUTANEOUS T-CELL LYMPHOMA PIPELINE ANALYTICS BY DRUG CLASS
• TABLE 14: CUTANEOUS T-CELL LYMPHOMA PIPELINE ANALYTICS BY MECHANISM OF ACTION
• TABLE 15: CUTANEOUS T-CELL LYMPHOMA PIPELINE ANALYTICS BY MOLECULE TYPE
• TABLE 16: MAJOR MERGERS AND ACQUISITIONS IN CUTANEOUS T-CELL LYMPHOMA THERAPEUTIC AREA
• TABLE 17: MAJOR COLLABORATION AGREEMENTS IN CUTANEOUS T-CELL LYMPHOMA THERAPEUTIC AREA
• TABLE 18: MAJOR LICENSING AGREEMENTS IN CUTANEOUS T-CELL LYMPHOMA THERAPEUTIC AREA
• TABLE 19: MAJOR FINANCING AGREEMENTS IN CUTANEOUS T-CELL LYMPHOMA THERAPEUTIC AREA
• TABLE 20: MAJOR TERMINATION AND SETTLEMENT AGREEMENTS IN CUTANEOUS T-CELL LYMPHOMA THERAPEUTIC AREA
• TABLE 21: COMPANIES LOOKING FOR CORPORATE PARTNERING, LICENSING, FUNDING OPPORTUNITIES
• TABLE 22: ESTIMATED R&D INVESTMENTS OF NEW ENTRANTS

LIST OF FIGURES

(COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

• FIGURE 01: CUTANEOUS T-CELL LYMPHOMA FORECASTED PREVALENCE & INCIDENCE OF US, EUROPE AND CHINA, 2020 V/S 2030
• FIGURE 02: GLOBAL CUTANEOUS T-CELL LYMPHOMA POPULATION (2020) FORECAST (2021-2030)
• FIGURE 03: US CUTANEOUS T-CELL LYMPHOMA POPULATION (2020) FORECAST (2021-2030)
• FIGURE 04: GLOBAL CUTANEOUS T-CELL LYMPHOMA MARKET CURRENT (2020) AND FORECAST (2021-2030)
• FIGURE 05: US CURRENT (2020) CUTANEOUS T-CELL LYMPHOMA MARKET VALUE COMPARED WITH GLOBAL MARKET (M$)
• FIGURE 06: YEAR BY YEAR COMPARISON OF CUTANEOUS T-CELL LYMPHOMA MARKET VALUES GLOBAL VS USA (2020 - 2030) (M$)
• FIGURE 07: CUTANEOUS T-CELL LYMPHOMA PIPELINE DRUGS ANALYTICS
• FIGURE 08: CUTANEOUS T-CELL LYMPHOMA PIPELINE DRUGS ANALYTICS BY HSD
• FIGURE 09: CUTANEOUS T-CELL LYMPHOMA PIPELINE ANALYTICS BY ROA
• FIGURE 10: CUTANEOUS T-CELL LYMPHOMA PIPELINE ANALYTICS BY DRUG CLASS
• FIGURE 11: CUTANEOUS T-CELL LYMPHOMA PIPELINE ANALYTICS BY DRUG CLASS VERSUS HSD
• FIGURE 12: CUTANEOUS T-CELL LYMPHOMA PIPELINE ANALYTICS BY MECHANISM OF ACTION
• FIGURE 13: CUTANEOUS T-CELL LYMPHOMA PIPELINE ANALYTICS BY MOLECULE TYPE
• FIGURE 14: CUTANEOUS T-CELL LYMPHOMA PIPELINE ANALYTICS BY COMPANY TYPE
• FIGURE 15: CUTANEOUS T-CELL LYMPHOMA DEALS ANALYTICS BY DEAL TYPE

GervanoRA's pipeline analysis and opportunity assessment report, "Cutaneous T-Cell Lymphoma - Epidemiology Based Current (2021) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal Worth Assessments, r-NPV and Pipeline Drugs Analytics H1 2022" analysed and assessed Cutaneous T-Cell Lymphoma pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Cutaneous T-Cell Lymphoma drugs industry.

The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the Cutaneous T-Cell Lymphoma area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in Cutaneous T-Cell Lymphoma drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Drug Class, Pipeline Analytics by Molecule Type, Pipeline Analytics by Molecule Target and Pipeline Analytics by Company Type.

The report delivers an in-depth understanding of the Cutaneous T-Cell Lymphoma historical and forecasted epidemiology based market trends Worldwide, the United States, EU8 (Poland, Spain, Switzerland, Sweden, Italy, Germany, Austria, France), United Kingdom and China. A detailed analytics on the Current Cutaneous T-Cell Lymphoma Market (2021) and the Forecasted Cutaneous T-Cell Lymphoma Market until the year 2030 for the regions have been provided.

Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the Emerging companies in the domain based on In-Licensing opportunities, Out-Licensing opportunities, Corporate Partnering opportunities and funding opportunities. The report even aimed to conduct the Risk-Adjusted Net Present Value (RNPV) Analysis with its Excel based r-NPV analysis model to help companies in licensing negotiations, technology valuations and pipeline asset valuation and establishing the value for licensing deal. It also aims to provide the sales potential of the drugs along with the new drugs pricing and pricing strategies.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

• Epidemiological Studies - Historical Trends and Probabilistic Epidemiology Forecast

• Epidemiology Based Market Estimations - Current Market Value and Market Forecast

• Plotting of the Anticipated Market Share for the New Entrants

• Pricing Strategies of New Entrants Supported Through KOL Insights

• Risk-Adjusted Net Present Value (RNPV) Analysis

• Comparative Pipeline Insights and Benchmarking Snapshots by HSD, Geography, RoA, Drug Class, MoA, Molecule Target, Molecule Type

• Unmet Needs and Opportunities

• Comparative Patent Analytics of Cutaneous T-Cell Lymphoma Pipeline Drugs

• Competitive Opportunity Assessments of the Active Players in the Cutaneous T-Cell Lymphoma Therapeutic Space by Partnering, Licensing and Funding Opportunities

• Deals Activities of Cutaneous T-Cell Lymphoma Therapeutic Space

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: CUTANEOUS T-CELL LYMPHOMA OVERVIEW AND EPIDEMIOLOGICAL STUDIES

CHAPTER 4: CUTANEOUS T-CELL LYMPHOMA CURRENT MARKET VALUE AND FORECAST 2021 - 2030

CHAPTER 5: COMPARATIVE PIPELINE INSIGHTS AND BENCHMARKING SNAPSHOTS

CHAPTER 6: DEALS ACTIVITIES OF CUTANEOUS T-CELL LYMPHOMA COMPETITIVE SPACE

CHAPTER 7: COMPARATIVE PATENT ANALYTICS OF CUTANEOUS T-CELL LYMPHOMA PIPELINE DRUGS

CHAPTER 8: RISK-ADJUSTED NET PRESENT VALUE (R-NPV) ANALYSIS

CHAPTER 9: COMPETITIVE OPPORTUNITY ASSESSMENTS

CHAPTER 10: MARKET DYNAMICS

CHAPTER 11: COMPETITOR NEW DRUGS PRICING STRATEGIES